Alzheimer's

Disappointing GLP-1 Results in Alzheimer’s Trial: Underscores Promise (and Limits) of Single-Agent Approaches

GLP-1s and Alzheimer's

Scientists have studied Alzheimer’s disease for over a century, since Alois Alzheimer’s initial description of brain abnormalities in a patient with presenile dementia. Today, amyloid‑beta plaques and tau tangles are recognized as hallmarks of the disease, though its causes are complex and multifactorial.

Read More

Cracking the Code: How Epigenetics and Blood Tests Are Changing the Alzheimer's Landscape

Cracking the Code: How Epigenetics and Blood Tests Are Changing the Alzheimer’s Landscape

Alzheimer’s disease, a condition that slowly erodes memory and cognitive function, has long been one of the most formidable challenges in medicine. With a rapidly growing patient population in the U.S., the impact of Alzheimer’s disease is profound and far reaching.

Read More

Subscribe to Our Blog

Be the first to receive exclusive life science articles directly to your inbox. Monthly news articles include interviews, webinars and insights from life science experts.

The information you provide will be used in accordance with the terms of our privacy policy.